Tag: Lisocabtagene maraleucel

Approximately 40% of non-Hodgkin lymphoma patients do not respond to initial chemotherapy, highlighting the need for advanced treatments. **Is Breyanzi an immunotherapy?** Yes, it is—specifically, it is an innovative type of CAR T-cell therapy that uses a patient's own modified immune cells to attack cancer.

First approved by the FDA in February 2021, Breyanzi (lisocabtagene maraleucel) is a revolutionary and personalized form of cancer treatment. So, what is the generic name for Breyanzi? It is lisocabtagene maraleucel, a highly specialized and individualized cellular immunotherapy. This therapy is developed for each patient using their own genetically modified immune cells to fight specific blood cancers.